Company Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally.
It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer.
It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus.
It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions.
It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer.
The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
| Country | United States |
| Founded | 1991 |
| IPO Date | Oct 5, 1995 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,700 |
| CEO | Paul Diaz |
Contact Details
Address: 322 North 2200 West Salt Lake City, Utah 84116 United States | |
| Phone | 801 584 3600 |
| Website | myriad.com |
Stock Details
| Ticker Symbol | MYGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000899923 |
| CUSIP Number | 62855J104 |
| ISIN Number | US62855J1043 |
| Employer ID | 87-0494517 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Samraat S. Raha | Chief Operating Officer |
| Dr. Dale Muzzey Ph.D. | Chief Scientific Officer |
| Mark S. Verratti | Chief Commercial Officer |
| Scott J. Leffler | Chief Financial Officer |
| Natalie Munk | Principal Accounting Officer |
| Dr. Kevin Richard Haas Ph.D. | Chief Technology Officer |
| Matthew Scalo | Senior Vice President of Investor Relations |
| Jennifer L. Fox | Chief Legal Officer |
| Glenn Farrell | Senior Vice President and Chief Marketing Officer |
| Shereen Solaiman | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 11, 2024 | 144 | Filing |
| Oct 9, 2024 | 8-K | Current Report |
| Sep 16, 2024 | 144 | Filing |
| Sep 11, 2024 | 144 | Filing |
| Sep 11, 2024 | 144 | Filing |
| Sep 9, 2024 | 144 | Filing |
| Sep 4, 2024 | 8-K | Current Report |